Investigating the Variability among Indicators for Quantifying Antimicrobial Use in the Intensive Care Units: Analysis of Real-world Evidence

被引:0
|
作者
Deshwal, Prity R. [1 ]
Tiwari, Pramil [1 ]
机构
[1] Natl Inst Pharmaceut Educ & Res NIPER, Dept Pharm Practice, Mohali, Punjab, India
关键词
Antimicrobial use; Days of therapy; Defined daily dose; Length of therapy; Prescribed daily dose; Real-world evidence; INFECTIOUS-DISEASES SOCIETY; ANTIBACTERIAL DRUG-USE; STEWARDSHIP; EPIDEMIOLOGY; GUIDELINES; AMERICA; VALIDATION; RESISTANCE; HOSPITALS; PROGRAM;
D O I
10.5005/jp-journals-10071-24745
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
This study investigated variability among four indicators for quantifying antimicrobial use in intensive care units (ICUs): defined daily doses (DDD), prescribed daily doses (PDD), duration of therapy (DOT), and length of therapy (LOT) and recommended the most clinically relevant approach. Retrospective data from patients who had received at least one antimicrobial was analyzed. Patients whose records were incomplete or expired were excluded. Duration of therapy (24433/1000 PDs) and LOTs (12832/1000 PDs) underestimated the overall consumption of antimicrobials compared with DDD of 28391/1000 PDs. Whereas PDD (46699/1000 PDs) overestimated it. Comparison analysis detected % differences of 13.94, 23.92, and 54.80% between DDD and DOT, DDD and PDD, and DDD and LOT, indicators respectively. Linear regression revealed stronger ( r 2 = 0.86), moderate ( r 2 = 0.50), and moderate ( r 2 = 0.60) correlation between DDD and DOT, DDD and PDD and DDD and LOT indicators respectively. According to findings, combining DOT and DDD is a more practical method to quantify antimicrobial consumption in hospital ICUs.
引用
收藏
页码:662 / 676
页数:15
相关论文
共 50 条
  • [31] Burden of Pneumonia Among Hospitalized Patients with Influenza: Real-World Evidence from a US Managed Care Population
    Bolge, Susan C.
    Gutierrez, Cynthia
    Kariburyo, Furaha
    He, Ding
    PULMONARY THERAPY, 2021, 7 (02) : 517 - 532
  • [32] Use of inhaled corticosteroids in preschool children and variability among pediatricians: a real-world analysis before and during the SARS-CoV-2 pandemic
    Alagna, Michela
    Clavenna, Antonio
    Reali, Laura
    Lallo, Adele
    Fusco, Danilo
    Davoli, Marina
    Di Martino, Mirko
    BMC PEDIATRICS, 2023, 23 (01)
  • [33] Use of inhaled corticosteroids in preschool children and variability among pediatricians: a real-world analysis before and during the SARS-CoV-2 pandemic
    Michela Alagna
    Antonio Clavenna
    Laura Reali
    Adele Lallo
    Danilo Fusco
    Marina Davoli
    Mirko Di Martino
    BMC Pediatrics, 23
  • [34] A COMPARATIVE PRODUCT CONSUMPTION ANALYSIS AMONG NEW STOMA APPLIANCE USERS UTILIZING REAL-WORLD EVIDENCE
    Andersen, F. B.
    Snow-Tyler, A.
    Hakan-Bloch, J.
    VALUE IN HEALTH, 2022, 25 (07) : S600 - S600
  • [35] Real-world evidence on health resource use among patients with haemophilia and inhibitor exhibiting severe bleeding episodes
    Chuansumrit, Ampaiwan
    Sirachainan, Nongnuch
    Natesirinilkul, Rungrote
    Srikala, Kwannut
    Masaya-anon, Narongrit
    HAEMOPHILIA, 2021, 27 (01) : 69 - 80
  • [36] Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States
    Hankosky, Emily R.
    Desai, Karishma
    Chinthammit, Chanadda
    Grabner, Michael
    Stockbower, Grace
    He, Xuanyao
    Mojdami, Donna
    Wenziger, Cachet
    Gibble, Theresa Hunter
    DIABETES & METABOLISM, 2025, 51 (03)
  • [37] The impact of COVID-19 pandemic on the dynamic HIV care engagement among people with HIV: real-world evidence
    Yang, Xueying
    Zhang, Jiajia
    Chen, Shujie
    Weissman, Sharon
    Olatosi, Bankole
    Li, Xiaoming
    AIDS, 2023, 37 (06) : 951 - 956
  • [38] Healthcare Resources Use in Patients with Human Immunodeficiency Virus (HIV). Real-World Evidence From Six Italian Local Health Units
    Perrone, Valentina
    Sangiorgi, Diego
    Buda, Stefano
    Andretta, Margherita
    Borre, Silvio
    Cattaruzzi, Chiara
    Gasperini, Gina
    Lena, Fabio
    Pisterna, Alessia
    Degli Esposti, Luca
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2018, 19 (01) : 37 - 45
  • [39] Real-world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the Veradigm® database
    Gibble, Theresa Hunter
    Chinthammit, Chanadda
    Ward, Jennifer M.
    Cappell, Katherine
    Sedgley, Robert
    Bonafede, Machaon
    Liao, Birong
    Hankosky, Emily R.
    DIABETES OBESITY & METABOLISM, 2025,
  • [40] Luminous: Results from the 2014 Interim Analysis to Provide Further Real-World Evidence for Clinical Ranibizumab Use
    Brand, Christopher
    OPHTHALMOLOGICA, 2014, 232 : 4 - 5